[go: up one dir, main page]

ZA200409430B - Process for the manufacture of quinoline derivatives. - Google Patents

Process for the manufacture of quinoline derivatives.

Info

Publication number
ZA200409430B
ZA200409430B ZA200409430A ZA200409430A ZA200409430B ZA 200409430 B ZA200409430 B ZA 200409430B ZA 200409430 A ZA200409430 A ZA 200409430A ZA 200409430 A ZA200409430 A ZA 200409430A ZA 200409430 B ZA200409430 B ZA 200409430B
Authority
ZA
South Africa
Prior art keywords
manufacture
quinoline derivatives
formula
quinoline
chaineded
Prior art date
Application number
ZA200409430A
Other languages
English (en)
Inventor
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of ZA200409430B publication Critical patent/ZA200409430B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200409430A 2002-06-12 2004-11-23 Process for the manufacture of quinoline derivatives. ZA200409430B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives

Publications (1)

Publication Number Publication Date
ZA200409430B true ZA200409430B (en) 2006-02-22

Family

ID=20288148

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200409430A ZA200409430B (en) 2002-06-12 2004-11-23 Process for the manufacture of quinoline derivatives.

Country Status (28)

Country Link
EP (1) EP1511732B9 (is)
JP (1) JP4584709B2 (is)
KR (1) KR100979216B1 (is)
CN (1) CN100418950C (is)
AT (1) ATE348814T1 (is)
AU (1) AU2003228195B2 (is)
BR (1) BR0311674A (is)
CA (1) CA2487329C (is)
CY (1) CY1107555T1 (is)
DE (1) DE60310554T2 (is)
DK (1) DK1511732T5 (is)
ES (1) ES2278160T3 (is)
HR (1) HRP20050028B1 (is)
IL (1) IL165155A (is)
IS (1) IS2975B (is)
ME (1) ME00435B (is)
MX (1) MXPA04012276A (is)
NO (1) NO329162B1 (is)
NZ (1) NZ536768A (is)
PL (1) PL210259B1 (is)
PT (1) PT1511732E (is)
RS (1) RS51021B (is)
RU (1) RU2291861C2 (is)
SE (1) SE0201778D0 (is)
SI (1) SI1511732T1 (is)
UA (1) UA78310C2 (is)
WO (1) WO2003106424A1 (is)
ZA (1) ZA200409430B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
WO2007047863A2 (en) 2005-10-19 2007-04-26 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
KR20090083479A (ko) 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
DK2234485T3 (da) 2007-12-20 2014-02-10 Teva Pharma Stabile laquinimod-præparater
UA104005C2 (ru) 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
US20120009226A1 (en) * 2008-12-17 2012-01-12 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
MX2012001333A (es) 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
EP2542078B1 (en) 2010-03-03 2015-10-07 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
MX2012010066A (es) 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
BR112013000599A2 (pt) 2010-07-09 2016-07-05 Teva Pharma deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações
EA021171B1 (ru) * 2010-07-09 2015-04-30 Эктив Байотек Аб Способ получения хинолин-3-карбоксамидов
WO2012006544A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EA201490748A1 (ru) 2011-10-12 2014-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза комбинацией лахинимода и финголимода
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
SG11201404419WA (en) 2012-02-16 2014-10-30 Teva Pharma N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
KR20150091077A (ko) 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
EP3137092A4 (en) 2014-04-29 2017-10-11 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN107108510B (zh) 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺
EP3180005B1 (en) 2014-11-19 2017-12-27 Active Biotech AB Quinoline carboxamides for use in the treatment of leukemia
KR20220149579A (ko) 2020-03-03 2022-11-08 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
PL4185292T3 (pl) 2020-07-23 2025-10-13 Erasmus University Medical Center Rotterdam Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnych
MX2023008016A (es) 2021-01-18 2023-07-13 Active Biotech Ab Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
JP2024524158A (ja) 2021-07-02 2024-07-05 アクティブ バイオテック エイビー タスキニモドを含有する医薬製品および前記製品の純度を評価する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
IS7550A (is) 2004-11-24
KR20050016537A (ko) 2005-02-21
DE60310554D1 (de) 2007-02-01
SI1511732T1 (sl) 2007-06-30
WO2003106424A1 (en) 2003-12-24
JP4584709B2 (ja) 2010-11-24
ME00435B (me) 2011-10-10
NO329162B1 (no) 2010-08-30
EP1511732B1 (en) 2006-12-20
CY1107555T1 (el) 2013-03-13
CA2487329C (en) 2010-11-16
PT1511732E (pt) 2007-03-30
PL210259B1 (pl) 2011-12-30
MXPA04012276A (es) 2005-04-08
JP2005535612A (ja) 2005-11-24
DK1511732T3 (da) 2007-04-30
BR0311674A (pt) 2008-01-08
KR100979216B1 (ko) 2010-08-31
DE60310554T2 (de) 2007-11-29
AU2003228195B2 (en) 2009-05-28
RU2005100054A (ru) 2005-07-10
EP1511732B9 (en) 2008-11-12
PL373817A1 (en) 2005-09-19
RS107604A (sr) 2007-02-05
CA2487329A1 (en) 2003-12-24
ES2278160T3 (es) 2007-08-01
HRP20050028A2 (en) 2006-02-28
IL165155A0 (en) 2005-12-18
CN1659146A (zh) 2005-08-24
CN100418950C (zh) 2008-09-17
RU2291861C2 (ru) 2007-01-20
DK1511732T5 (da) 2007-10-01
HRP20050028B1 (hr) 2013-07-31
NZ536768A (en) 2006-10-27
ATE348814T1 (de) 2007-01-15
IS2975B (is) 2017-07-15
SE0201778D0 (sv) 2002-06-12
EP1511732A1 (en) 2005-03-09
IL165155A (en) 2009-11-18
AU2003228195A1 (en) 2003-12-31
RS51021B (sr) 2010-10-31
UA78310C2 (en) 2007-03-15
NO20045703L (no) 2004-12-29

Similar Documents

Publication Publication Date Title
ZA200409430B (en) Process for the manufacture of quinoline derivatives.
CA2446944A1 (en) Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use
NO20044767L (no) Farmasoytisk formulering med modifisert frigjoring
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
MY141020A (en) Novel pparalpha and ppargamma agonists
NO20055099L (no) Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
WO2003024913A1 (en) SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY
NO20031046L (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
TW200720234A (en) Hydroxynaphthalenedicarboxylic acid hydrazide and derivatives thereof as well as process for preparing them
AU5209600A (en) Orally active androgens
NO20055924L (no) Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater
WO2001083423A3 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof
ES2184633A1 (es) Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
ATE337348T1 (de) Beschichtungen aus speziellen polyolen und oxalsäure
TW200621807A (en) Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound
NO20044045L (no) Ny fremgangsmate
AU6520498A (en) Process for producing piperidinecarboxylic acid amides
UA42554A (uk) Спосіб отримання 7-заміщених 3-метил-8-(піперазиніл-1) ксантинів, що мають антианафілактичну активність